WHO Recommends GLP-1 Drugs for Long-Term Obesity Treatment
Update: 2025-12-01
Description
The World Health Organization (WHO) has endorsed GLP-one drugs like Ozempic and Wegovy for long-term obesity treatment, marking a shift in recognizing obesity as a chronic disease. These drugs mimic a natural hormone to reduce appetite and aid weight loss. The WHO urges governments to make these treatments more affordable and accessible, as high costs and limited supply currently hinder many people. The global patent for semaglutide, the main ingredient in these drugs, is set to expire in some countries next year, potentially lowering prices. The WHO emphasizes that these therapies should be used alongside behavioral therapy and regular counseling.
The Daily News Now! - Every city. Every story. Powered by AI.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
